Literature DB >> 17060363

Factors masking HMGB1 in human serum and plasma.

Vilma Urbonaviciute1, Barbara G Fürnrohr, Christian Weber, Martin Haslbeck, Sabine Wilhelm, Martin Herrmann, Reinhard E Voll.   

Abstract

High mobility group box 1 protein (HMGB1) is a ubiquitously expressed architectural chromosomal protein. Recently, it has become obvious that HMGB1 can also act as a proinflammatory mediator when actively secreted during cell activation or passively released from necrotic cells. HMGB1 appears to play an important role in the pathogenesis of diseases, including sepsis and rheumatoid arthritis. However, easy, sensitive, and reliable detection systems are required to investigate the clinical significance of HMGB1 in clinical samples for diagnosis and prognosis of diseases. Here, we describe sensitive ELISAs for the detection of HMGB1 in cell culture medium and cell lysates. However, these assays failed to reliably quantitate HMGB1 in serum and plasma when compared with immunoblot analysis. We found that serum/plasma components bind to HMGB1 and interfere with its detection by ELISA systems. In most serum/plasma samples investigated, including those from healthy individuals, we detected IgG antibodies binding to HMGB1. The titers of these antibodies correlated with the capacity of sera to interfere with the detection of recombinant HMGB1 by ELISA. Furthermore, HMGB1 coimmunoprecipitated with several proteins including IgG1, as identified by mass spectrometry. These HMGB1 interacting proteins are currently characterized and may contribute to complex formation, masking, and possibly, modulation of cytokine activity of HMGB1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060363     DOI: 10.1189/jlb.0306196

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  65 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Post-translational modifications of high mobility group box 1 and cancer.

Authors:  Seidu A Richard; Yuanyuan Jiang; Lu Hong Xiang; Shanshan Zhou; Jia Wang; Zhaoliang Su; Huaxi Xu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  HMGb1 promotes scratch wound closure of HaCaT keratinocytes via ERK1/2 activation.

Authors:  Elia Ranzato; Mauro Patrone; Marco Pedrazzi; Bruno Burlando
Journal:  Mol Cell Biochem       Date:  2009-07-09       Impact factor: 3.396

4.  Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus.

Authors:  F Schaper; K de Leeuw; G Horst; F Maas; H Bootsma; P Heeringa; P C Limburg; J Westra
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

5.  Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-20

Review 6.  High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.

Authors:  Shu Zhu; Wei Li; Mary F Ward; Andrew E Sama; Haichao Wang
Journal:  Inflamm Allergy Drug Targets       Date:  2010-03

7.  Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.

Authors:  Xiaoping Qing; Milena Pitashny; David B Thomas; Franck J Barrat; Mark P Hogarth; Chaim Putterman
Journal:  Immunol Lett       Date:  2008-09-24       Impact factor: 3.685

8.  High-mobility group box-1 protein serum levels do not reflect monocytic function in patients with sepsis-induced immunosuppression.

Authors:  Nadine Unterwalder; Christian Meisel; Konstantinos Savvatis; Ben Hammoud; Christina Fotopoulou; Hans-Dieter Volk; Petra Reinke; Joerg C Schefold
Journal:  Mediators Inflamm       Date:  2010-06-21       Impact factor: 4.711

9.  HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis.

Authors:  Sari Karlsson; Ville Pettilä; Jyrki Tenhunen; Raili Laru-Sompa; Marja Hynninen; Esko Ruokonen
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

Review 10.  Alarmins, inflammasomes and immunity.

Authors:  Najwane Saïd-Sadier; David M Ojcius
Journal:  Biomed J       Date:  2012 Nov-Dec       Impact factor: 4.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.